Cefpodoxime

Cefpodoxime is a third-generation cephalosporin, one of a class of beta-lactam antibiotics valued for broad activity and for resistance to many bacterial enzymes ^[1][2]. It is administered by mouth in the form of cefpodoxime proxetil, an ester prodrug that is itself inactive; esterases in the intestinal wall remove the proxetil group during absorption and release active cefpodoxime into the bloodstream ^[2]. The active molecule has the formula C15H17N5O6S2 and a molar mass of about 427 grams per mole, and it carries the aminothiazole and methoxyimino groups characteristic of this generation of cephalosporins ^[1].

Cefpodoxime is active against a wide array of gram-positive and gram-negative bacteria, among them Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, Moraxella catarrhalis, and many Enterobacteriaceae, and it retains activity against numerous beta-lactamase-producing strains ^[2][4]. Unlike the closely related oral cephalosporin cefixime, it keeps meaningful activity against methicillin-susceptible Staphylococcus aureus ^[2]. It is not effective against Pseudomonas aeruginosa, enterococci, or Bacteroides fragilis ^[1].

In clinical use the drug treats acute otitis media, pharyngitis and tonsillitis, sinusitis, community-acquired pneumonia and other lower respiratory infections, uncomplicated urinary tract infections, and skin and soft-tissue infections, and it has served as an oral option for uncomplicated gonorrhea ^[1][3][4]. Randomized comparative trials in adults and children have generally found cefpodoxime proxetil at least as effective as standard treatments such as amoxicillin, amoxicillin combined with clavulanic acid, cefaclor, cefuroxime, and cefixime, and in some studies an oral course matched the results of injected ceftriaxone in pneumonia ^[2][3]. The drug is also used as oral step-down therapy after an initial course of intravenous cephalosporin treatment ^[1].

Cefpodoxime shows oral bioavailability of roughly one-half, which improves when it is taken with food, along with modest protein binding and an elimination half-life of about two hours that allows twice-daily dosing ^[1][2]. It is cleared mainly by the kidneys in unchanged form ^[1]. The medicine is available only by prescription and is supplied as oral tablets and as a powder for suspension; it is also marketed for veterinary use ^[1]. It is generally well tolerated, and its safety profile resembles that of other oral beta-lactam antibiotics ^[3].

Cefpodoxime is prescription only. The most common effects are diarrhea, nausea, abdominal pain, and, in some people, vaginal yeast infection. Like other broad antibiotics it can disturb gut flora and, less often, trigger Clostridioides difficile colitis. Allergic reactions range from rash to, rarely, severe hypersensitivity, and people with a serious penicillin allergy have a small chance of cross-reaction. Its absorption depends on stomach acid, so antacids, H2 blockers, and proton pump inhibitors reduce how much is taken up and should be separated in time. Probenecid raises drug levels by slowing kidney clearance. It is used with dose adjustment in significant kidney impairment. Finish the whole course to avoid leaving resistant bacteria behind.

Cefpodoxime proxetil is an ester prodrug whose absorption depends on gastric acidity, and its main interaction follows from that. High-dose antacids containing sodium bicarbonate or aluminium hydroxide, and H2 receptor antagonists, lower peak plasma cefpodoxime by 24% to 42% and total absorption by 27% to 32%; proton pump inhibitors are expected to behave similarly. The rate of absorption is unchanged, only the amount, so the consequence is underexposure and possible treatment failure rather than mere delay, and dosing is conventionally separated by at least two hours.

Probenecid works in the opposite direction, blocking renal tubular secretion of cefpodoxime and raising AUC by about 31% and peak levels by about 20%.

Aminoglycosides and potent diuretics such as furosemide add to the risk of renal injury when given with a cephalosporin, particularly where renal function is already impaired.

As with other broad-spectrum antibacterials, disruption of gut flora can raise INR in people taking warfarin, and cefpodoxime blunts the response to live oral typhoid vaccine.

Checking a whole stack? Run it through interactions + stacks.

Cefpodoxime was developed by the Japanese pharmaceutical company Sankyo as part of the search for orally active third-generation cephalosporins, molecules that combined the broad gram-negative reach of the injectable third-generation drugs with the convenience of a tablet. The compound was first patented in 1980, and to overcome the poor intestinal absorption typical of the class the chemists esterified it into the proxetil prodrug, an inactive form that is cleaved to the active antibiotic during passage through the gut wall.

It reached medical use in 1989 and was introduced under brand names including Vantin in the United States and Orelox in Europe. Its stability against many plasmid-encoded beta-lactamase enzymes, together with a roughly two-hour half-life suited to twice-daily dosing, established it as a practical option for respiratory, urinary, and skin infections. Over the following decades it moved off patent and became widely available as an inexpensive generic.

Cefpodoxime is regarded as a dependable, broad-spectrum oral cephalosporin that brings much of the antibacterial range once reserved for injectable agents into outpatient practice. Clinicians value its activity against common respiratory and urinary pathogens, its beta-lactamase stability, and a tolerability profile in which gastrointestinal upset is the most frequent complaint.

Comparative trials have generally shown it to be similar in clinical and bacteriological efficacy to established agents such as amoxicillin, cefaclor, and amoxicillin-clavulanate rather than clearly superior, and reviewers have noted that some of the early literature carried methodological limitations. It is well tolerated by children and has been used for otitis media and pharyngitis. As with all cephalosporins, its usefulness is tempered by the broader concern of preserving these drugs against rising bacterial resistance.